Free Access
Med Sci (Paris)
Volume 29, Number 12, Décembre 2013
Page(s) 1131 - 1137
Section M/S Revues
Published online 20 December 2013
  1. Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 2008 ; 65 : 672–686. [CrossRef] [PubMed] [Google Scholar]
  2. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000 ; 12 : 634–640. [CrossRef] [PubMed] [Google Scholar]
  3. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998 ; 93 : 1159–1170. [CrossRef] [PubMed] [Google Scholar]
  4. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990 ; 87 : 6624–6628. [CrossRef] [Google Scholar]
  5. Malek MH, Olfert IM. Global deletion of thrombospondin-1 increases cardiac and skeletal muscle capillarity and exercise capacity in mice. Exp Physiol 2009 ; 94 : 749–760. [CrossRef] [PubMed] [Google Scholar]
  6. Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 2008 ; 9 : 851–862. [CrossRef] [PubMed] [Google Scholar]
  7. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001 ; 98 : 12485–12490. [CrossRef] [Google Scholar]
  8. Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. Faseb J 2009 ; 23 : 3368–3376. [CrossRef] [PubMed] [Google Scholar]
  9. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010 ; 285 : 38923–38932. [CrossRef] [PubMed] [Google Scholar]
  10. Smadja DM, d’Audigier C, Bieche I, et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 2011 ; 31 : 551–559. [CrossRef] [PubMed] [Google Scholar]
  11. Xie HH, Zhou S, Chen DD, et al. GTP cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and thrombospondin-1 in salt-sensitive hypertension. Hypertension 2010 ; 56 : 1137–1144. [CrossRef] [PubMed] [Google Scholar]
  12. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009 ; 9 : 182–194. [CrossRef] [PubMed] [Google Scholar]
  13. Jin G, Tsuji K, Xing C, et al. CD47 gene knockout protects against transient focal cerebral ischemia in mice. Exp Neurol 2009 ; 217 : 165–170. [CrossRef] [PubMed] [Google Scholar]
  14. Brechot N, Gomez E, Bignon M, et al. Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PloS One 2008 ; 3 : e3950. [CrossRef] [PubMed] [Google Scholar]
  15. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int Immunol 2006 ; 18 : 689–699. [CrossRef] [PubMed] [Google Scholar]
  16. Grimbert P, Bouguermouh S, Baba N, et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol 2006 ; 177 : 3534–3541. [PubMed] [Google Scholar]
  17. Lamy L, Foussat A, Brown EJ, et al. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 2007 ; 178 : 5930–5939. [PubMed] [Google Scholar]
  18. Li Z, Calzada MJ, Sipes JM, et al. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 2002 ; 157 : 509–519. [CrossRef] [PubMed] [Google Scholar]
  19. Vallejo AN, Mugge LO, Klimiuk PA, et al. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. J Immunol 2000 ; 164 : 2947–2954. [PubMed] [Google Scholar]
  20. Yamauchi Y, Kuroki M, Imakiire T, et al. Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937. Biochem Biophys Res Commun 2002 ; 290 : 1551–1557. [CrossRef] [PubMed] [Google Scholar]
  21. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 2002 ; 161 : 831–839. [CrossRef] [PubMed] [Google Scholar]
  22. Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010 ; 120 : 2782–2794. [CrossRef] [PubMed] [Google Scholar]
  23. Yang K, Vega JL, Hadzipasic M, et al. Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2009 ; 32 : 94–103. [CrossRef] [PubMed] [Google Scholar]
  24. Narizhneva NV, Razorenova OV, Podrez EA, et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. Faseb J 2005 ; 19 : 1158–1160. [PubMed] [Google Scholar]
  25. Martin-Manso G, Navarathna DH, Galli S, et al. Endogenous thrombospondin-1 regulates leukocyte recruitment, activation, accelerates death from systemic candidiasis. PloS One 2012 ; 7 : e48775. [CrossRef] [PubMed] [Google Scholar]
  26. McMaken S, Exline MC, Mehta P, et al. Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PloS One 2011 ; 6 : e19654. [CrossRef] [PubMed] [Google Scholar]
  27. Thakar CV, Zahedi K, Revelo MP, et al. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 2005 ; 115 : 3451–3459. [CrossRef] [PubMed] [Google Scholar]
  28. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001 ; 12 : 1434–1447. [PubMed] [Google Scholar]
  29. Bige N, Shweke N, Benhassine S, et al. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int 2012 ; 81 : 1226–1238. [CrossRef] [PubMed] [Google Scholar]
  30. Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001 ; 37 : 601–611. [CrossRef] [PubMed] [Google Scholar]
  31. Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005 ; 48 : 2650–2660. [CrossRef] [PubMed] [Google Scholar]
  32. Hochegger K, Knight S, Hugo C, et al. Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis. Nephron 2004 ; 96 : e31–e38. [PubMed] [Google Scholar]
  33. Hugo C, Shankland SJ, Pichler RH, et al. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998 ; 53 : 302–311. [CrossRef] [PubMed] [Google Scholar]
  34. Rogers NM, Thomson AW, Isenberg JS. Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J Am Soc Nephrol 2012 ; 23 : 1538–1550. [CrossRef] [PubMed] [Google Scholar]
  35. Yung S, Lee CY, Zhang Q, et al. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol Dial Transplant 2006 ; 21 : 1504–1513. [CrossRef] [PubMed] [Google Scholar]
  36. Naito T, Masaki T, Nikolic-Paterson DJ, et al. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol 2004 ; 286 : F278–F287. [Google Scholar]
  37. Hugo C, Pichler R, Meek R, et al. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int 1995 ; 48 : 1846–1856. [CrossRef] [PubMed] [Google Scholar]
  38. Han SH, Yang S, Jung DS, et al. Gene expression patterns in glucose-stimulated podocytes. Biochem Biophys Res Commun 2008 ; 370 : 514–518. [CrossRef] [PubMed] [Google Scholar]
  39. Sheibani N, Morrison ME, Gurel Z, et al. BIM deficiency differentially impacts the function of kidney endothelial and epithelial cells through modulation of their local microenvironment. Am J Physiol 2012 ; 302 : F809–F819. [Google Scholar]
  40. Daniel C, Wiede J, Krutzsch HC, et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 2004 ; 65 : 459–468. [CrossRef] [PubMed] [Google Scholar]
  41. Lu A, Miao M, Schoeb TR, et al. Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011 ; 178 : 2573–2586. [CrossRef] [PubMed] [Google Scholar]
  42. Xie XS, Li FY, Liu HC, et al. LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction. Arch Pharmacal Res 2010 ; 33 : 275–284. [CrossRef] [Google Scholar]
  43. Daniel C, Takabatake Y, Mizui M, et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003 ; 163 : 1185–1192. [CrossRef] [PubMed] [Google Scholar]
  44. Daniel C, Schaub K, Amann K, et al. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 2007 ; 56 : 2982–2989. [CrossRef] [PubMed] [Google Scholar]
  45. McGregor B, Colon S, Mutin M, et al. Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. Am J Pathol 1994 ; 144 : 1281–1287. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.